Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559919 | 0.78 | ALDH1A1 (0.40) | ALDH1A1LMNASMN1; SMN2NPC1POLB | |
| SCHEMBL7894809 | 0.78 | KCNMA1 (0.38) | ALDH1A1LMNASMN1; SMN2HPGDGAA | |
| SCHEMBL30751791 | 0.78 | ALDH1A1 (0.40) | ALDH1A1LMNASMN1; SMN2NPC1POLB | |
| SCHEMBL15691383 | 0.77 | ALDH1A1 (0.39) | ALDH1A1LMNASMN1; SMN2NPC1POLB | |
| SCHEMBL1721807 | 0.75 | PSMD14 (0.40) | ALDH1A1LMNASMN1; SMN2NPC1POLB | |
| SCHEMBL677194 | 0.75 | L3MBTL1 (0.45) | ALDH1A1LMNASMN1; SMN2NPC1POLB | |
| SCHEMBL1261198 | 0.75 | NOS2 (0.54) | ALDH1A1LMNASMN1; SMN2NPC1POLB | |
| SCHEMBL3828718 | 0.75 | ALDH1A1 (0.44) | ALDH1A1LMNASMN1; SMN2NPC1POLB | |
| SCHEMBL16539264 | 0.75 | ALDH1A1 (0.38) | ALDH1A1LMNASMN1; SMN2NPC1POLB | |
| SCHEMBL27158634 | 0.75 | SMN1; SMN2 (0.40) | ALDH1A1LMNASMN1; SMN2NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1064265-B8 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMA (US) | 2004-10-13 | — | — | EP | claimed |
| EP-1064265-B1 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMA (US) | 2004-04-14 | — | — | EP | claimed |
| EP-1064265-A4 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMA (US) | 2003-02-12 | — | — | EP | claimed |
| EP-1064265-A1 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2001-01-03 | — | — | EP | claimed |
| US-6111112-A | Synthesis of 3-amino-2-chloro-4-methylpyridine from malononitrile and acetone | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-08-29 | — | — | US | claimed |
| WO-2000043365-A1 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | claimed |
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | disclosed |
| CN-116120287-B | Heteroaromatic carboxamide derivatives as inhibitors of plasma kallikrein | 勃林格殷格翰国际有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-03-07 | — | — | US | disclosed |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-01-04 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| EP-1064265-B8 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMA (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1064265-B1 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMA (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1064265-A4 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMA (US) | 2003-02-12 | — | — | EP | disclosed |
| EP-1064265-A1 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2001-01-03 | — | — | EP | disclosed |
| US-6111112-A | Synthesis of 3-amino-2-chloro-4-methylpyridine from malononitrile and acetone | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-08-29 | — | — | US | disclosed |
| WO-2000043365-A1 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-0017768-A1 | Reactive dyestuffs and their use | BASF Aktiengesellschaft (DE) | 1980-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ALDH1A1 1223/4885LMNA 2081/4885SMN1; SMN2 4693/4885 |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ALDH1A1 1223/4885LMNA 2081/4885SMN1; SMN2 4693/4885 |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ALDH1A1 1223/4885LMNA 2081/4885SMN1; SMN2 4693/4885 |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ALDH1A1 1223/4885LMNA 2081/4885SMN1; SMN2 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.